Search clinical trials for: Tubulin polymerization inhibitor

Total 71937 results

University Hospital Inselspital, Berne
University of Bern; Hospital Centre Biel/Bienne

Recruiting

Guiding Instillation in Non Muscle-invasive Bladder Cancer Based on Drug Screens in Patient Derived Organoids

Bladder Cancer | Non-muscle Invasive

Switzerland
National Cancer Institute (NCI)

Recruiting

Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Metastatic NUT Carcinoma | Unresectable NUT Carcinoma | Advanced NUT Carcinoma

United States
Baylor Breast Care Center

Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer (RESPONSE)

Breast Cancer | Breast Neoplasm | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Estrogen Receptor-positive Breast Cancer | Hormone Receptor-positive Breast Cancer | Breast Cancer Invasive

United States
Fujian Cancer Hospital

Not yet recruiting

Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer

Advanced Triple Negative Breast Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.

Non Small Cell Lung Cancer

China
Ruijin Hospital

Recruiting

The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

Diffuse Large B Cell Lymphoma

China
Fundación GECP

Recruiting

Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases (NIVIPI-Brain)

Lung Cancer | Non Small Cell Lung Cancer | Brain Metastases, Adult

Spain
AGO Study Group
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Recruiting

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cancer

Germany
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Merck Sharp & Dohme LLC

Recruiting

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Hepatocellular Carcinoma | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Neoplasms

United States, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, Turkey, Canada
Xencor, Inc.

Recruiting

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States
Fudan University

Recruiting

Induction Chemotherapy and Toripalimab for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma (INSIGHT)

Laryngeal Cancer | Laryngeal Neoplasms | Hypopharynx Cancer

China
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma

Alveolar Rhabdomyosarcoma | Embryonal Rhabdomyosarcoma | Botryoid-Type Embryonal Rhabdomyosarcoma | Spindle Cell Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma | Metastatic Embryonal Rhabdomyosarcoma | Metastatic Rhabdomyosarcoma | Solid Alveolar Rhabdomyosarcoma

United States, Canada, Australia, Puerto Rico, Saudi Arabia
Acotec Scientific Co., Ltd

Recruiting

Acoart SCB SFA: Sirolimus Coated Balloon Catheter in the Treatment of Femoropopliteal Artery Stenosis

Peripheral Artery Disease

China
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Akeso

Recruiting

A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Cervical Cancer

China
M.D. Anderson Cancer Center

Recruiting

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Diffuse Large B-Cell Lymphoma

United States
Sun Yat-sen University

Recruiting

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

Recurrent Cervical Cancer | Stage IVB Cervical Cancer | Persistent Cervical Cancer

China
Peking Union Medical College Hospital

Not yet recruiting

Toripalimab Combined With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Cervical Cancer

Cervical Cancer

China
Samsung Medical Center

Recruiting

Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases (PHOEBS)

Non-small Cell Lung Cancer

Korea, Republic of
Merck Sharp & Dohme LLC
Eisai Inc.

Recruiting

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Metastatic Esophageal Squamous Cell Carcinoma

Argentina, Chile, United States, Canada, China, Costa Rica, Denmark, France, Guatemala, Hong Kong, Hungary, Italy, Japan, Korea, Republic of, Russian Federation, Spain, Taiwan, Turkey, United Kingdom, Romania, Ukraine, Singapore, Ma... and more
St Vincent's Hospital, Sydney

Recruiting

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer (4CAST)

Triple Negative Breast Cancer

Australia
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of N9 Chemotherapy in Children With Neuroblastoma

Neuroblastoma | Pediatric Cancer

United States
Wuhan Union Hospital, China

Recruiting

Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC (NEOSUN)

Non Small Cell Lung Cancer

China
CanariaBio Inc.
Korean Cancer Study Group

Recruiting

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Ovarian Cancer Stage IV | Ovarian Cancer Stage III | Ovarian Cancer by FIGO Stage

Korea, Republic of
Chipscreen Biosciences, Ltd.

Recruiting

Chiauranib Plus Weekly Paclitaxel in Patients With Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer (CHIPRO)

Ovarian Cancer | Relapsed or Refractory | Chiauranib | Paclitaxel

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Squamous Cell Carcinoma

China
Second Affiliated Hospital, School of Medicine,...
Changhai Hospital; Shanxi Province Cancer Hospital; The First Affiliated Hospital... and other collaborators

Recruiting

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Peripheral T-Cell Lymphoma | Lenalidomide | CHOP

China
Hallym University Medical Center

Not yet recruiting

Real-world Data (RWD) of Ramucirumab Plus Paclitaxel

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of
Peking Union Medical College Hospital

Recruiting

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Intravascular Large B-Cell Lymphoma

China
Bristol-Myers Squibb

Recruiting

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...

United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
M.D. Anderson Cancer Center

Recruiting

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage IIIC Lung Cancer AJCC v8 | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC v7

United States
Celgene

Recruiting

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

Lymphoma, B-Cell

United States, Greece, Spain, Australia, Poland, Taiwan, Korea, Republic of
Fondazione Ricerca Traslazionale

Recruiting

Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (COMBI-TED)

Metastatic Non Small Cell Lung Cancer

France, Spain, Italy
Wuhan University

Recruiting

SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy (SABRE)

Non-Small Cell Lung Cancer

China
Guangdong Provincial People's Hospital

Recruiting

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC (NeoSACT)

Triple Negative Breast Cancer

China
IRCCS San Raffaele
Bristol-Myers Squibb

Recruiting

An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo) (NURE-Combo)

Muscle-Invasive Bladder Carcinoma

Italy
Massachusetts General Hospital
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Recruiting

Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout (TRUST)

Gout

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Breast Cancer | Hormone-receptor Positive Breast Cancer

China
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

Breast Cancer

Korea, Republic of, United States, Australia, China, Ukraine, Spain, United Kingdom, Turkey, Mexico, Brazil, Belgium, Denmark, Germany, Greece, Portugal, Russian Federation, Taiwan, France, Kenya, Thailand, Romania, Italy, Czechia, Hu... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
University Hospital Heidelberg
Dietmar Hopp Stiftung

Recruiting

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)

NSCLC Stage IIIB | NSCLC Stage II | NSCLC, Stage IIIA

Germany
Ohio State University Comprehensive Cancer Center

Recruiting

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Recruiting

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Head Neck Cancer | Oropharynx Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
Tufts Medical Center
Partner Therapeutics, Inc.

Recruiting

A Study of Sargramostim Plus Pembrolizumab With or Without Pemetrexed in Patients With Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy

Advanced Lung Non-Small Cell Carcinoma | Non-Small Cell Carcinoma of Lung, TNM Stage 4

United States
Yazeed Sawalha

Recruiting

Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma

United States
Fudan University

Recruiting

PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP

Cancer of Unknown Primary

China
The First Affiliated Hospital with Nanjing Medical...

Recruiting

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Metastatic NSCLC | Recurrent NSCLC | Advanced Non-Small Cell Squamous Lung Cancer

China
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Sun Yat-sen University

Not yet recruiting

R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study

DLBCL

Search clinical trials for: Tubulin polymerization inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations